Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001531 · ClinicalTrials.gov registry record
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 355
- Enrollment target
NCT00001531 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 355 participants.
The verdict
NCT00001531 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients without atherosclerosis is influenced by prior CMV exposure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 1996-06 |
| Est. Completion | 2000-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001531
The ClinicalTrials.gov registry entry for NCT00001531 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001531 about?
NCT00001531 is a clinical study titled "Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction". The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients without atherosclerosis is influenced by prior CMV exposure.
What is the current status of trial NCT00001531?
This trial is currently completed. The enrollment target is 355 participants. The study started on 1996-06. Estimated completion is 2000-09.
Who is sponsoring clinical trial NCT00001531?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.